Literature DB >> 17120035

Neurofibromatosis presenting with a cherubism phenotype.

C I van Capelle1, P H G Hogeman, C J M van der Sijs-Bos, B G F Heggelman, B Idowu, P J Slootweg, A R M Wittkampf, A M Flanagan.   

Abstract

We report on a child who presented clinical manifestations of both neurofibromatosis type 1 (NF1) and cherubism. With genetic testing, we found a mutation in the NF-1 gene, confirming the neurocutaneous disorder. Histology when correlated with radiological evaluation of a mandibular biopsy was consistent with cherubism. This is the first report in the literature of a child with proven neurofibromatosis type 1 and cherubism without extragnathic lesions. This emphasises that cherubism is a clinical phenotype that can be associated with a number of germline mutations involving SH3BP2, PTPN11 and NF1.

Entities:  

Mesh:

Year:  2006        PMID: 17120035     DOI: 10.1007/s00431-006-0334-6

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  29 in total

1.  Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism.

Authors:  Y Ueki; V Tiziani; C Santanna; N Fukai; C Maulik; J Garfinkle; C Ninomiya; C doAmaral; H Peters; M Habal; L Rhee-Morris; J B Doss; S Kreiborg; B R Olsen; E Reichenberger
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

2.  Clinical and radiological features of central giant-cell lesions of the jaw.

Authors:  Jan De Lange; Hans P Van den Akker
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2005-04

3.  The Noonan syndrome/cherubism association.

Authors:  C Dunlap; B Neville; R A Vickers; D O'Neil; B Barker
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1989-06

4.  Disseminated nonossifying fibromas in association with café-au-lait spots (Jaffe-Campanacci syndrome).

Authors:  J M Mirra; R H Gold; F Rand
Journal:  Clin Orthop Relat Res       Date:  1982-08       Impact factor: 4.176

5.  Evaluation of denaturing high performance liquid chromatography (DHPLC) for the mutational analysis of the neurofibromatosis type 1 ( NF1) gene.

Authors:  S S Han; D N Cooper; M N Upadhyaya
Journal:  Hum Genet       Date:  2001-10-11       Impact factor: 4.132

6.  Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation.

Authors:  Steven A Lietman; Natasha Kalinchinko; Xichao Deng; Ronald Kohanski; Michael A Levine
Journal:  Hum Mutat       Date:  2006-07       Impact factor: 4.878

7.  Cherubism: diagnosis, treatment, and comparison with central giant cell granulomas and giant cell tumors.

Authors:  G E Kaugars; J Niamtu; J A Svirsky
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1992-03

8.  Is Jaffe-Campanacci syndrome just a manifestation of neurofibromatosis type 1?

Authors:  Randall S Colby; Robert A Saul
Journal:  Am J Med Genet A       Date:  2003-11-15       Impact factor: 2.802

9.  A novel PTPN11 gene mutation bridges Noonan syndrome, multiple lentigines/LEOPARD syndrome and Noonan-like/multiple giant cell lesion syndrome.

Authors:  Anna Sarkozy; Maria Gabriela Obregon; Emanuela Conti; Giorgia Esposito; Rita Mingarelli; Antonio Pizzuti; Bruno Dallapiccola
Journal:  Eur J Hum Genet       Date:  2004-12       Impact factor: 4.246

10.  A missense mutation in the SH3BP2 gene on chromosome 4p16.3 found in a case of nonfamilial cherubism.

Authors:  Yoshimichi Imai; Kiyoshi Kanno; Takuya Moriya; Shuji Kayano; Hiroto Seino; Yoichi Matsubara; Atsushi Yamada
Journal:  Cleft Palate Craniofac J       Date:  2003-11
View more
  9 in total

1.  Cherubism misdiagnosed as giant cell tumor: a case report and review of literature.

Authors:  Yang Jiao; Mi Zhou; Yaowu Yang; Jun Zhou; Xiaohong Duan
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 2.  Benefits of molecular pathology in the diagnosis of musculoskeletal disease : Part II of a two-part review: bone tumors and metabolic disorders.

Authors:  Adrienne M Flanagan; David Delaney; Paul O'Donnell
Journal:  Skeletal Radiol       Date:  2009-08-11       Impact factor: 2.199

3.  Neurofibromatosis Type 1 With Cherubism-like Phenotype, Multiple Osteolytic Bone Lesions of Lower Extremities, and Alagille-syndrome: Case Report With Literature Survey.

Authors:  Reinhard E Friedrich; Jozef Zustin; Andreas M Luebke; Thorsten Rosenbaum; Martin Gosau; Christian Hagel; Felix K Kohlrusch; Ilse Wieland; Martin Zenker
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

4.  Cherubism combined with epilepsy, mental retardation and gingival fibromatosis (Ramon syndrome): a case report.

Authors:  J Suhanya; Chakshu Aggarwal; Khadijah Mohideen; S Jayachandran; I Ponniah
Journal:  Head Neck Pathol       Date:  2009-12-11

Review 5.  Cherubism: best clinical practice.

Authors:  Maria E Papadaki; Steven A Lietman; Michael A Levine; Bjorn R Olsen; Leonard B Kaban; Ernst J Reichenberger
Journal:  Orphanet J Rare Dis       Date:  2012-05-24       Impact factor: 4.123

Review 6.  The role of SH3BP2 in the pathophysiology of cherubism.

Authors:  Ernst J Reichenberger; Michael A Levine; Bjorn R Olsen; Maria E Papadaki; Steven A Lietman
Journal:  Orphanet J Rare Dis       Date:  2012-05-24       Impact factor: 4.123

Review 7.  Giant cell lesions of the craniofacial bones.

Authors:  Adrienne M Flanagan; Paul M Speight
Journal:  Head Neck Pathol       Date:  2014-11-20

8.  Multiple giant cell lesions in patients with Noonan syndrome and cardio-facio-cutaneous syndrome.

Authors:  Thomas E Neumann; Judith Allanson; Ines Kavamura; Bronwyn Kerr; Giovanni Neri; Jacqueline Noonan; Viviana Cordeddu; Kate Gibson; Andreas Tzschach; Gabriele Krüger; Maria Hoeltzenbein; Timm O Goecke; Hans Gerd Kehl; Beate Albrecht; Klaudiusz Luczak; Maria M Sasiadek; Luciana Musante; Rohan Laurie; Hartmut Peters; Marco Tartaglia; Martin Zenker; Vera Kalscheuer
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

9.  Fibrous dysplasia and cherubism.

Authors:  Surajit Bhattacharya; R K Mishra
Journal:  Indian J Plast Surg       Date:  2015 Sep-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.